As of Q4'25, Pfizer's P/B Ratio stands at 1.52, reflecting a slight increase from the previous quarter's value of 1.49. This latest data point marks a modest recovery after a period of decline, suggesting a stabilization in the company's price-to-book valuation toward the end of the observed period. Over the timeframe from Q1'23 to Q4'25, the P/B Ratio has generally trended downward, falling from 2.14 in Q1'23 to its current level. The ratio experienced intermittent fluctuations, with brief rebounds in Q2'24 and Q2'25, but the overall pattern indicates a gradual compression in valuation. This trend may reflect changing market sentiment or adjustments in Pfizer's underlying book value relative to its share price.